Leerink Partners reiterated an Outperform rating and $145.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ahead of ALN-PCSsc Ph I data. The data is scheduled to be presented at the ESC conference on August 30th. ALNY will also release additional important pipeline data for 2H15 at the conference.

Analyst Michael Schmidt commented, "We continue to recommend ALNY with an OP rating following the recent weakness and ahead of ALN-PCSsc Ph I data to be presented at the ESC conference on Aug. 30th and addl. important pipeline data in 2H15. We believe data on 'PCSsc safety/tolerability, as well as magnitude, duration and consistency of LDL-C reduction should provide important insights into possible differentiating features from PCSK9 antibodies and see addl. upside for ALNY shares into ESC and over the rest of the year. Maintaining OP rating and $145 PT."

For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.

Shares of Alnylam Pharmaceuticals closed at $105.74 yesterday.